SH2D1A and cancer: XIAP-deficient patients also never experience lymphoma in contrast to patients with SAP deficiency, likely related to the anti-apoptotic function of XIAP, which may protect patients from cancer, and XIAP is now considered as a promising therapeutic target for cancer treatment (64).